How Can We Treat Mitochondrial Encephalomyopathies? Approaches to Therapy

Neurotherapeutics

Volumn 5, Issue 4, 2008, Pages 558-568

  Horvath, Rita ^a   Gorman, Grainne ^a   Chinnery, Patrick F ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

coenzyme Q10; exercise; genetic counseling; Mitochondrial disease; pharmacological therapy; trials

Indexed keywords

BENZODIAZEPINE; CREATINE; DICHLOROACETIC ACID; DIMETHYLGLYCINE; ETIRACETAM; PHENYTOIN; RIBOFLAVIN; SODIUM CHANNEL BLOCKING AGENT; TOPIRAMATE; UBIQUINONE; VALPROIC ACID;

ARTICLE; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA REPLICATION; DRUG MEGADOSE; EXERCISE; GENE MUTATION; GENE THERAPY; GENETIC COUNSELING; GENOTYPE; GERM LINE GENE THERAPY; HUMAN; KEARNS SAYRE SYNDROME; KETOGENIC DIET; LEIGH DISEASE; MELAS SYNDROME; MERRF SYNDROME; MITOCHONDRIAL ENCEPHALOMYOPATHY; MORBIDITY; MORTALITY; NEUROPATHY; NEUROPROTECTION; NONVIRAL GENE THERAPY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; SAGUENAY LAC SAINT JEAN CYTOCHROME OXIDASE DEFICIENCY; SEIZURE; SURVIVAL RATE; VIRAL GENE THERAPY;

ANIMALS; DISEASE PROGRESSION; EXERCISE THERAPY; GENE THERAPY; HUMANS; MITOCHONDRIAL ENCEPHALOMYOPATHIES; NOOTROPIC AGENTS; ORGAN TRANSPLANTATION;

EID: 53049094677     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2008.07.002     Document Type: Article

References (94)

1. Zeviani M., and Carelli V. Mitochondrial disorders. Curr Opin Neurol 20 (2007) 564-571
2. DiMauro S., and Schon E.A. Mitochondrial respiratory-chain diseases. N Engl J Med 348 (2003) 2656-2668
3. Schon E.A., and DiMauro S. Mitochondrial mutations: genotype to phenotype. Novartis Found Symp 287 (2007) 214-225
4. DiMauro S., and Mancuso M. Mitochondrial diseases: therapeutic approaches. Biosci Rep 27 (2007) 125-137
5. Chinnery P., Majamaa K., Turnbull D., and Thorburn D. Treatment for mitochondrial disorders. Cochrane Database Syst Rev 1 (2006) CD004426
6. Chinnery P.F., Bindoff L.A., and European Neuromuscular Center. 116th ENMC International Workshop: the treatment of mitochondrial disorders, 14th-16th March 2003, Naarden, The Netherlands. Neuromuscul Disord 13 (2003) 757-764
7. Chinnery P.F. New approaches to the treatment of mitochondrial disorders. Reprod Biomed Online 8 (2004) 16-23
8. DiMauro S., Mancuso M., and Naini A. Mitochondrial encephalomyopathies: therapeutic approach. Ann N Y Acad Sci 1011 (2004) 232-245
9. DiMauro S., Hirano M., and Schon E.A. Approaches to the treatment of mitochondrial diseases. Muscle Nerve 34 (2006) 265-283
10. Schaefer A.M., McFarland R., Blakely E.L., et al. Prevalence of mitochondrial DNA disease in adults. Ann Neurol 63 (2008) 35-39
11. Clark K.M., Bindoff L.A., Lightowlers R.N., et al. Reversal of a mitochondrial DNA defect in human skeletal muscle. Nat Genet 16 (1997) 222-224
12. Chen R.S., Huang C.C., and Chu N.S. Coenzyme Q10 treatment in mitochondrial encephalomyopathies: short-term double-blind, crossover study. Eur Neurol 37 (1997) 212-218
13. Muller W., Reimers C.D., Berninger T., Boergen K.-P., Frey A., Zrenner E., et al. Coenzyme Q10 in ophthalmoplegia plus: a double blind cross over therapeutic trial. J Neurol Sci 98 Suppl (1990) 442 (abstract)
14. Tarnopolsky M.A., Roy B.D., and MacDonald J.R. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve 20 (1997) 1502-1509
15. Klopstock T., Querner V., Schmidt F., et al. A placebo-controlled crossover trial of creatine in mitochondrial diseases. Neurology 55 (2000) 1748-1751
16. De Stefano N., Matthews P.M., Ford B., Genge A., Karpati G., and Arnold D.L. Short-term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders. Neurology 45 (1995) 1193-1198
17. Liet J.M., Pelletier V., Robinson B.H., et al. The effect of short-term dimethylglycine treatment on oxygen consumption in cytochrome oxidase deficiency: a double-blind randomized crossover clinical trial. J Pediatr 142 (2003) 62-66
18. Kaufmann P., Engelstad K., Wei Y., et al. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology 66 (2006) 324-330
19. Tein I., DiMauro S., Xie Z.W., and De Vivo D.C. Valproic acid impairs carnitine uptake in cultured human skin fibroblasts: an in vitro model for the pathogenesis of valproic acid-associated carnitine deficiency. Pediatr Res 34 (1993) 281-287
20. Krähenbühl S., Brandner S., Kleinle S., Liechti S., and Straumann D. Mitochondrial disease represents a risk factor for valproate induced fulminant liver failure. Liver 20 (2000) 346-349
21. Kollberg G., Moslemi A.R., Darin N., et al. POLG1 mutations associated with progressive encephalopathy in childhood. J Neuropathol Exp Neurol 65 (2006) 758-768
22. Tzoulis C., Engelsen B.A., Telstad W., et al. The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases. Brain 129 (2006) 1685-1692
23. Gibbs J.E., Walker M.C., and Cock H.R. Levetiracetam: antiepileptic properties and protective effects on mitochondrial dysfunction in experimental status epilepticus. Epilepsia 47 (2006) 469-478
24. Kang H.C., Lee Y.M., Kim H.D., Lee J.S., and Slama A. Safe and effective use of the ketogenic diet in children with epilepsy and mitochondrial respiratory chain complex defects. Epilepsia 48 (2007) 82-88
25. Luoma P., Melberg A., Rinne J.O., et al. Parkinsonism, premature menopause, and mitochondrial DNA polymerase γ mutations: clinical and molecular genetic study. Lancet 364 (2004) 875-882
26. Lys. Neurology 68 (2007) 56-58
27. Sinnathuray A.R., Raut V., Awa A., Magee A., and Toner J.G. A review of cochlear implantation in mitochondrial sensorineural hearing loss. Otol Neurotol 24 (2003) 418-426
28. Sue C.M., Lipsett L.J., Crimmins D.S., et al. Cochlear origin of hearing loss in MELAS syndrome. Ann Neurol 43 (1998) 350-359
29. Yu Wai Man C.Y., Chinnery P.F., and Griffiths P.G. Extraocular muscles have fundamentally distinct properties that make them selectively vulnerable to certain disorders. Neuromuscul Disord 15 (2005) 17-23
30. Yu Wai Man C.Y., Smith T., Chinnery P.F., Turnbull D.M., and Griffiths P.G. Assessment of visual function in chronic progressive external ophthalmoplegia. Eye 20 (2006) 564-568
31. Wong V.A., Beckingsale P.S., Oley C.A., and Sullivan T.J. Management of myogenic ptosis. Ophthalmology 109 (2002) 1023-1031
32. Hutnik C.M., and Nichols B.D. Cataracts in systemic diseases and syndromes. Curr Opin Ophthalmol 10 (1999) 22-28
33. Hom X.B., and Lavine J.E. Gastrointestinal complications of mitochondrial disease. Mitochondrion 4 (2004) 601-607
34. Guillausseau P.J., Dubois-Laforgue D., Massin P., et al. Mitochondrial Diabetes French Study Group. Heterogeneity of diabetes phenotype in patients with 3243 bp mutation of mitochondrial DNA (maternally inherited diabetes and deafness or MIDD). Diabetes Metab 30 (2004) 181-186
35. Holmgren D., Wåhlander H., Eriksson B.O., Oldfors A., Holme E., and Tulinius M. Cardiomyopathy in children with mitochondrial disease: clinical course and cardiological findings. Eur Heart J 24 (2003) 280-288
36. Bindoff L. Mitochondria and the heart. Eur Heart J 24 (2003) 221-224
37. Bonnet D., Rustin P., Rötig A., et al. Heart transplantation in children with mitochondrial cardiomyopathy. Heart 86 (2001) 570-573
38. Bhati R.S., Sheridan B.C., Mill M.R., and Selzman C.H. Heart transplantation for progressive cardiomyopathy as a manifestation of MELAS syndrome. J Heart Lung Transplant 24 (2005) 2286-2289
39. Mangat J., Lunnon-Wood T., Rees P., Elliott M., and Burch M. Successful cardiac transplantation in Barth syndrome: single-centre experience of four patients. Pediatr Transplant 11 (2007) 327-331
40. Santorelli F.M., Gagliardi M.G., Dionisi-Vici C., et al. Hypertrophic cardiomyopathy and mtDNA depletion: successful treatment with heart transplantation. Neuromuscul Disord 12 (2002) 56-59
41. Copeland W.C. Inherited mitochondrial diseases of DNA replication. Annu Rev Med 59 (2008) 131-146
42. Dimmock D.P., Dunn J.K., Feigenbaum A., et al. Neurological phenotype is an important predictor of long term outcome in mitochondrial DNA depletion resulting from deoxyguanosine kinase deficiency. Liver Transpl (2008) (in press)
43. Horvath R., Hudson G., Ferrari G., et al. Phenotypic spectrum associated with mutations of the mitochondrial polymerase γ gene. Brain 129 (2006) 1674-1684
44. De Vivo D.C., and DiMauro S. Mitochondrial diseases. In: Swaiman K.F., and Ashwal S. (Eds). Pediatric neurology: principles & practice. 3rd ed. (1999), Mosby, St Louis 494-509
45. Nishino I., Spinazzola A., and Hirano M. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science 283 (1999) 689-692
46. Yavuz H., Ozel A., Christensen M., et al. Treatment of mitochondrial neurogastrointestinal encephalomyopathy with dialysis. Arch Neurol 64 (2007) 435-438
47. Hirano M., Martí R., Casali C., et al. Allogeneic stem cell transplantation corrects biochemical derangements in MNGIE. Neurology 67 (2006) 1458-1460
48. DiMauro S., Quinzii C.M., and Hirano M. Mutations in coenzyme Q10 biosynthetic genes. J Clin Invest 117 (2007) 587-589
49. Haas R.H. The evidence basis for coenzyme Q therapy in oxidative phosphorylation disease. Mitochondrion 7 Suppl (2007) S136-S145
50. Shults C.W., and Haas R. Clinical trials of coenzyme Q10 in neurological disorders. Biofactors 25 (2005) 117-126
51. Cochemé H.M., Kelso G.F., James A.M., et al. Mitochondrial targeting of quinones: therapeutic implications. Mitochondrion 7 Suppl (2007) S94-S102
52. Yamada Y., Akita H., Kogure K., Kamiya H., and Harashima H. Mitochondrial drug delivery and mitochondrial disease therapy: an approach to liposome-based delivery targeted to mitochondria. Mitochondrion 7 (2007) 63-71
53. Rötig A., Appelkvist E.L., Geromel V., et al. Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet 356 (2000) 391-395
54. Van Maldergem L., Trijbels F., DiMauro S., et al. Coenzyme Q-responsive Leigh's encephalopathy in two sisters. Ann Neurol 52 (2002) 750-754
55. Di Giovanni S., Mirabella M., Spinazzola A., et al. Coenzyme Q10 reverses pathological phenotype and reduces apoptosis in familial CoQ10 deficiency. Neurology 57 (2001) 515-518
56. Quinzii C., Naini A., Salviati L., et al. A mutation in para-hydroxybenzoate-polyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency. Am J Hum Genet 78 (2006) 345-349
57. López L.C., Schuelke M., Quinzii C.M., et al. Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. Am J Hum Genet 79 (2006) 1125-1130
58. Mollet J., Giurgea I., Schlemmer D., et al. Prenyldiphosphate synthase, subunit 1 (PDSS1) and OH-benzoate polyprenyltransferase (COQ2) mutations in ubiquinone deficiency and oxidative phosphorylation disorders. J Clin Invest 117 (2007) 765-772
59. Quinzii C.M., López L.C., Von-Moltke J., et al. Respiratory chain dysfunction and oxidative stress correlate with severity of primary CoQ10 deficiency. FASEB J 22 (2008) 1874-1885
60. Ferrante K.L., Shefner J., Zhang H., et al. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology 65 (2005) 1834-1836
61. Quinzii C.M., Kattah A.G., Naini A., et al. Coenzyme Q deficiency and cerebellar ataxia associated with an aprataxin mutation. Neurology 64 (2005) 539-541
62. Lagier-Tourenne C., Tazir M., López L.C., et al. ADCK3, an ancestral kinase, is mutated in a form of recessive ataxia associated with coenzyme Q10 deficiency. Am J Hum Genet 82 (2008) 661-672
63. Lamperti C., Naini A., Hirano M., et al. Cerebellar ataxia and coenzyme Q10 deficiency. Neurology 60 (2003) 1206-1208
64. Horvath R., Schneiderat P., Schoser B.G.H., et al. Coenzyme Q10 deficiency may cause isolated myopathy. Neurology 66 (2006) 253-255
65. Gempel K., Topaloglu H., Talim B., et al. The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene. Brain 130 (2007) 2037-2044
66. Olsen R.K., Olpin S.E., Andresen B.S., et al. ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. Brain 130 (2007) 2045-2054
67. Di Prospero N.A., Baker A., Jeffries N., and Fischbeck K.H. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomized, placebo-controlled trial. Lancet Neurol 6 (2007) 878-886
68. Argov Z., Bank W.J., Maris J., et al. Treatment of mitochondrial myopathy due to complex III deficiency with vitamins K3 and C: A 31P-NMR follow-up study. Ann Neurol 19 (1986) 598-602
69. Keightley J.A., Anitori R., Burton M.D., Quan F., Buist N.R., and Kennaway N.G. Mitochondrial encephalomyopathy and complex III deficiency associated with a stop-codon mutation in the cytochrome b gene. Am J Hum Genet 67 (2000) 1400-1410
70. Freisinger P., Horvath R., Macmillan C., Peters J., and Jaksch M. Reversion of hypertrophic cardiomyopathy in a patient with deficiency of the mitochondrial copper binding protein Sco2: is there a potential effect of copper?. J Inherit Metab Dis 27 (2004) 67-79
71. Taanman J.W., Muddle J.R., and Muntau A.C. Mitochondrial DNA depletion can be prevented by dGMP and dAMP supplementation in a resting culture of deoxyguanosine kinase-deficient fibroblasts. Hum Mol Genet 12 (2003) 1839-1845
72. Beal M.F. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 58 (2005) 495-505
73. Mancuso C., Scapagini G., Currò D., et al. Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front Biosci 12 (2007) 1107-1123
74. Rodriguez M.C., MacDonald J.R., Mahoney D.J., Parise G., Beal M.F., and Tarnopolsky M.A. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 35 (2007) 235-242
75. Taylor R.W., Chinnery P.F., Turnbull D.M., and Lightowlers R.N. Selective inhibition of mutant human mitochondrial DNA replication in vitro by peptide nucleic acids. Nat Genet 15 (1997) 212-215
76. Chinnery P.F., Taylor R.W., Diekert K., Lill R., Turnbull D.M., and Lightowlers R.N. Peptide nucleic acid delivery to human mitochondria [Erratum in: Gene Ther 2000;7:813]. Gene Ther 6 (1999) 1919-1928
77. Kolesnikova O.A., Entelis N.S., Jacquin-Becker C., et al. Nuclear DNA-encoded tRNAs targeted into mitochondria can rescue a mitochondrial DNA mutation associated with the MERRF syndrome in cultured human cells. Hum Mol Genet 13 (2004) 2519-2534
78. Manfredi G., Gupta N., Vazquez-Memije M.E., et al. Oligomycin induces a decrease in the cellular content of a pathogenic mutation in the human mitochondrial ATPase 6 gene. J Biol Chem 274 (1999) 9386-9391
79. Santra S., Gilkerson R.W., Davidson M., and Schon E.A. Ketogenic treatment reduces deleted mitochondrial DNAs in cultured human cells. Ann Neurol 56 (2004) 662-669
80. Maalouf M., Sullivan P.G., Davis L., Kim D.Y., and Rho J.M. Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation. Neuroscience 145 (2007) 256-264
81. Taivassalo T., Fu K., Johns T., Arnold D., Karpati G., and Shoubridge E.A. Gene shifting: a novel therapy for mitochondrial myopathy. Hum Mol Genet 8 (1999) 1047-1052
82. Andrews R.M., Griffiths P.G., Chinnery P.F., and Turnbull D.M. Evaluation of bupivacaine-induced muscle regeneration in the treatment of ptosis in patients with chronic progressive external ophthalmoplegia and Kearns-Sayre syndrome. Eye 13 (1999) 769-772
83. Karadimas C.L., Greenstein P., Sue C.M., et al. Recurrent myoglobinuria due to a nonsense mutation in the COX I gene of mitochondrial DNA. Neurology 55 (2000) 644-649
84. Gardner J.L., Craven L., Turnbull D.M., and Taylor R.W. Experimental strategies towards treating mitochondrial DNA disorders. Biosci Rep 27 (2007) 139-150
85. Jeppesen T.D., Schwartz M., Olsen D.B., et al. Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy. Brain 129 (2006) 3402-3412
86. Taivassalo T., Gardner J.L., Taylor R.W., et al. Endurance training and detraining in mitochondrial myopathies due to single large-scale mtDNA deletions. Brain 129 (2006) 3391-3401
87. Brown D.T., Herbert M., Lamb V.K., et al. Transmission of mitochondrial DNA disorders: possibilities for the future. Lancet 368 (2006) 87-89
88. Gardner D.K., Sheehan C.B., Rienzi L., Katz-Jaffe M., and Larman M.G. Analysis of oocyte physiology to improve cryopreservation procedures. Theriogenology 67 (2007) 64-72
89. Steffann J., Feyereisen E., Kerbrat V., Romana S., and Frydman N. Prenatal and preimplantation genetic diagnosis: decision tree, new practices? [In French]. Med Sci (Paris) 21 (2005) 987-992
90. Cohen J., Scott R., Schimmel T., Levron J., and Willadsen S. Birth of infant after transfer of anucleate donor oocyte cytoplasm into recipient eggs. Lancet 350 (1997) 186-187
91. Roberts R.M. Prevention of human mitochondrial (mtDNA) disease by nucleus transplantation into an enucleated donor oocyte. Am J Med Genet 87 (1999) 265-266
92. McGrath J., and Solter D. Nuclear transplantation in the mouse embryo by microsurgery and cell fusion. Science 220 (1983) 1300-1302
93. Schaefer A.M., Phoenix C., Elson J.L., McFarland R., Chinnery P.F., and Turnbull D.M. Mitochondrial disease in adults: a scale to monitor progression and treatment. Neurology 66 (2006) 1932-1934
94. Phoenix C., Schaefer A.M., Elson J.L., et al. A scale to monitor progression and treatment of mitochondrial disease in children. Neuromuscul Disord 16 (2006) 814-820